Innovative development of the inspired sinewave device to measure lung functions and inhomogeneity for diagnosis and evaluations of early lung diseases

Surprisingly, lung disease is still one of the leading causes of deaths in the developed countries, including UK. According to the UK National Health Service (NHS), Chronic Obstructive Pulmonary Disease (COPD) is the fifth biggest killer disease in the UK, killing approximately 25,000 people a year. This prob-lem is even worse in developing countries such as Vietnam, India and China, where air pollution is a big problem and the disease awareness is under-recognised. The NHS has set out one of its challenges is to identify people with lung disease earlier in the disease’s development pathway, in order to pro-vide more effective and timely intervention and treatment. This paper presents a novel Inspired Sinewave Device (ISD) to measure lung function and inhomogeneity. Both set of infor-mation are important for diagnosis and detection of early lung diseases. ISD has the potential to replace or supplement the traditional spirometry in the routine lung function testing. The paper describes both the principle of ISD and a set of experi-mental results demonstrating the capability of ISD to asymp-totically detect asthmatic symptoms. Finally the paper discuss-es the future plan, including the testing of 300+ COPD patients at the Oxford Respiratory Trials Unit in UK, and the potential collaborations among research institutions in Vietnam and UK about cost-effective and innovative developments of smart devices, biosensors, lab-on-chips and telehealth solutions for the routine lung function testing, diagnosis and evaluations of early lung diseases

Fragile Mental Retardation Protein Interacts with the RNA-Binding Protein Caprin1 in Neuronal RiboNucleoProtein Complexes

Fragile X syndrome is caused by the absence of the Fragile X Mental Retardation Protein (FMRP), an RNA-binding protein. FMRP is associated with messenger RiboNucleoParticles (mRNPs) present in polyribosomes and its absence in neurons leads to alteration in synaptic plasticity as a result of translation regulation defects. The molecular mechanisms by which FMRP plays a role in translation regulation remain elusive. Using immunoprecipitation approaches with monoclonal Ab7G1-1 and a new generation of chicken antibodies, we identified Caprin1 as a novel FMRP-cellular partner. In vivo and in vitro evidence show that Caprin1 interacts with FMRP at the level of the translation machinery as well as in trafficking neuronal granules. As an RNA-binding protein, Caprin1 has in common with FMRP at least two RNA targets that have been identified as CaMKIIα and Map1b mRNAs. In view of the new concept that FMRP species bind to RNA regardless of known structural motifs, we propose that protein interactors might modulate FMRP functions

Wound dressings for a proteolytic-rich environment

Wound dressings have experienced continuous and significant changes over the years based on the knowledge of the biochemical events associated with chronic wounds. The development goes from natural materials used to just cover and conceal the wound to interactive materials that can facilitate the healing process, addressing specific issues in non-healing wounds. These new types of dressings often relate with the proteolytic wound environment and the bacteria load to enhance the healing. Recently, the wound dressing research is focusing on the replacement of synthetic polymers by natural protein materials to delivery bioactive agents to the wounds. This article provides an overview on the novel protein-based wound dressings such as silk fibroin keratin and elastin. The improved properties of these dressings, like the release of antibiotics and growth factors, are discussed. The different types of wounds and the effective parameters of healing process will be reviewed

Role of salt intake in prevention of cardiovascular disease: controversies and challenges.

Strong evidence indicates that reduction of salt intake lowers blood pressure and reduces the risk of cardiovascular disease (CVD). The WHO has set a global target of reducing the population salt intake from the current level of approximately 10 g daily to 85 categories of food; many other developed countries are following the UK's lead. In developing countries where most of the salt is added by consumers, public health campaigns have a major role. Every country should adopt a coherent, workable strategy. Even a modest reduction in salt intake across the whole population can lead to a major improvement in public health and cost savings

Pan-cancer analysis of whole genomes

Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale(1-3). Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4-5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter(4); identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation(5,6); analyses timings and patterns of tumour evolution(7); describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity(8,9); and evaluates a range of more-specialized features of cancer genomes(8,10-18).Peer reviewe

Innovative development of the inspired sinewave device to measure lung functions and inhomogeneity for diagnosis and evaluations of early lung diseases

Surprisingly, lung disease is still one of the leading causes of deaths in the developed countries, including UK. According to the UK National Health Service (NHS), Chronic Obstructive Pulmonary Disease (COPD) is the fifth biggest killer disease in the UK, killing approximately 25,000 people a year. This prob-lem is even worse in developing countries such as Vietnam, India and China, where air pollution is a big problem and the disease awareness is under-recognised. The NHS has set out one of its challenges is to identify people with lung disease earlier in the disease’s development pathway, in order to pro-vide more effective and timely intervention and treatment. This paper presents a novel Inspired Sinewave Device (ISD) to measure lung function and inhomogeneity. Both set of infor-mation are important for diagnosis and detection of early lung diseases. ISD has the potential to replace or supplement the traditional spirometry in the routine lung function testing. The paper describes both the principle of ISD and a set of experi-mental results demonstrating the capability of ISD to asymp-totically detect asthmatic symptoms. Finally the paper discuss-es the future plan, including the testing of 300+ COPD patients at the Oxford Respiratory Trials Unit in UK, and the potential collaborations among research institutions in Vietnam and UK about cost-effective and innovative developments of smart devices, biosensors, lab-on-chips and telehealth solutions for the routine lung function testing, diagnosis and evaluations of early lung diseases